These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19997771)

  • 1. Strategies for molecular expression profiling in bladder cancer.
    Mitra AP; Bartsch CC; Cote RJ
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):317-26. PubMed ID: 19997771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers in bladder cancer.
    Shariat SF; Karam JA; Lerner SP
    Curr Opin Urol; 2008 Jan; 18(1):1-8. PubMed ID: 18090481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder cancer outcome and subtype classification by gene expression.
    Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
    Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
    Mitra AP; Datar RH; Cote RJ
    J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
    van der Kwast TH; Bapat B
    Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers for detection, surveillance and prognostication of bladder cancer.
    Vrooman OP; Witjes JA
    Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
    Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
    Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nm23-H1 in the progression of transitional cell bladder cancer.
    Chow NH; Liu HS; Chan SH
    Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes.
    Wang X; Colby JK; Rengel RC; Fischer SM; Clinton SK; Klein RD
    Mol Carcinog; 2009 Jan; 48(1):1-13. PubMed ID: 18444251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic aspects of bladder cancer.
    Kim WJ; Quan C
    J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray.
    Ewis AA; El-Samman E; Ali N; Kajimoto K; Shinohara Y; Ishikawa M; Kanayama HO; Baba Y
    Urol Oncol; 2007; 25(2):120-7. PubMed ID: 17349526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
    van der Kwast TH
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.